Hologic’s big move: What happens when a health-tech giant goes private?

Hologic’s stock hit a year-high of $76. 07 recently, but the real story isn’t just the price—it’s the $18. 3 billion takeover by Blackstone and TPG that’s about to make the company private. The deal, expected to close by April 7, leaves investors with a simple choice: stick around for a possible bonus, cash out now, or jump in before it’s too late. The bonus? An extra $3 per share if Hologic’s breast health sales hit targets in 2026 and 2027. But here’s the catch: the stock is already trading at the buyout price, so buying now mostly bets on the deal closing on time—not on Hologic growing. Earlier this year, Hologic’s first-quarter results for 2026 missed expectations, with revenue up just 2. 5% to $1. 0478 billion and earnings slightly below forecasts. The company even paused guidance because of the takeover. Still, some bright spots exist—like FDA approval for a new cervical cancer screening test and a recent $350 million deal to acquire Gynesonics, a maker of ultrasound tech for fibroid treatments. But challenges remain, including a shortage of breast biopsy needles that could drag on results until late 2026.

Analysts are split. Some say the stock is fairly priced, with a possible upside if the CVR bonus pays out. Others warn the price is already high compared to rivals and point to risks like tariffs, weak diagnostics demand, and the biopsy shortage. Most have stuck with a "Hold" rating, expecting little growth once the company goes private. The deal’s approvals are locked in, but nothing is 100% certain—though the odds of failure seem slim. For investors, the decision comes down to priorities. Buying now means betting on the CVR payout or a quick closing. Selling locks in the $76 price but gives up any chance of extra cash. New buyers face minimal risk of the deal collapsing, but the upside is limited. The takeover isn’t just about Hologic—it’s part of a bigger trend where private equity targets stable, cash-flow-heavy companies in healthcare. Once private, Hologic will operate under the radar, free from Wall Street’s quarterly demands. That could mean more investment in innovation, but also less transparency. The next big question: Will the breast health segment deliver the growth needed for the CVR bonus? Private owners will have to steer that ship, and only time will tell if the gamble pays off.

Actions